272 related articles for article (PubMed ID: 22180676)
1. Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma.
Mansh M
Yale J Biol Med; 2011 Dec; 84(4):381-9. PubMed ID: 22180676
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Graziani G; Lisi L; Tentori L; Navarra P
Exp Suppl; 2022; 113():295-350. PubMed ID: 35165868
[TBL] [Abstract][Full Text] [Related]
3. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
5. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Lipson EJ; Drake CG
Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Letendre P; Monga V; Milhem M; Zakharia Y
Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Ascierto PA
Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Savoia P; Astrua C; Fava P
Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; CalabrĂ² L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
15. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Lotem M; Merims S; Frank S; Ospovat I; Peretz T
Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
[TBL] [Abstract][Full Text] [Related]
16. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.
Quirk SK; Shure AK; Agrawal DK
Transl Res; 2015 Nov; 166(5):412-24. PubMed ID: 26118951
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
19. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Callahan MK; Postow MA; Wolchok JD
Clin Dermatol; 2013; 31(2):191-9. PubMed ID: 23438382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]